Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: Goldman Sachs Cuts Next To Neutral From Buy

Mon, 11th May 2020 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

----------

FTSE 100

----------

GOLDMAN SACHS CUTS NEXT TO 'NEUTRAL' ('BUY') - PRICE TARGET 5300 PENCE

----------

JEFFERIES RAISES ASTRAZENECA PRICE TARGET TO 8,000 (7,575) PENCE - 'HOLD'

----------

BRYAN GARNIER RAISES ASTRAZENECA PRICE TARGET TO 8,780 (8,550) PENCE - 'BUY'

----------

CREDIT SUISSE CUTS EASYJET PRICE TARGET TO 746 (945) PENCE - 'OUTPERFORM

----------

MORGAN STANLEY CUTS LAND SECURITIES PRICE TARGET TO 740 (880) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY CUTS BRITISH LAND PRICE TARGET TO 450 (540) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY RAISES SEGRO PRICE TARGET TO 980 (950) PENCE - 'OVERWEIGHT'

----------

HSBC RAISES CARNIVAL TO 'BUY' ('HOLD') - TARGET 1280 (3500) PENCE

----------

BERENBERG RAISES OCADO PRICE TARGET TO 2225 (1725) PENCE - 'BUY'

----------

BERENBERG RAISES ST JAMES'S PLACE PRICE TARGET TO 875 (830) PENCE - 'HOLD'

----------

JPMORGAN CUTS RIO TINTO PRICE TARGET TO 4560 (4730) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS BHP GROUP PRICE TARGET TO 1780 (1830) PENCE - 'OVERWEIGHT'

----------

JPMORGAN CUTS ROLLS-ROYCE PRICE TARGET TO 155 (175) PENCE - 'UNDERWEIGHT'

----------

FTSE 250

----------

MORGAN STANLEY CUTS HAMMERSON TO 'UNDERWEIGHT' ('EQUAL-WEIGHT') - TARGET 50 (175) PENCE

----------

MORGAN STANLEY RAISES LONDONMETRIC PROPERTY TO 'EQUAL-WEIGHT' ('UNDERWEIGHT') - TARGET 200 (210) PENCE

----------

MORGAN STANLEY CUTS SHAFTESBURY PRICE TARGET TO 610 (770) PENCE - 'UNDERWEIGHT'

----------

MORGAN STANLEY CUTS GREAT PORTLAND PRICE TARGET TO 720 (920) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY CUTS DERWENT LONDON PRICE TARGET TO 3400 (4250) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY CUTS BIG YELLOW GROUP PRICE TARGET TO 900 (1000) PENCE - 'UNDERWEIGHT'

----------

MORGAN STANLEY RAISES IMI PRICE TARGET TO 980 (940) PENCE - 'EQUAL-WEIGHT'

----------

MORGAN STANLEY CUTS UNITE GROUP PRICE TARGET TO 950 (1300) PENCE - 'OVERWEIGHT'

----------

UBS RAISES TRAVIS PERKINS PRICE TARGET TO 1070 (1040) PENCE - 'NEUTRAL'

----------

HSBC CUTS WEIR GROUP TO 'HOLD' ('BUY') - TARGET 985 (1045) PENCE

----------

JPMORGAN CUTS BODYCOTE PRICE TARGET TO 530 (615) PENCE - 'NEUTRAL'

----------

GOLDMAN CUTS TATE & LYLE PRICE TARGET TO 740 (770) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

BERNSTEIN RAISES BOOHOO TO 'OUTPERFORM' ('MARKET-PERFORM') - TARGET 415 PENCE

----------

BERENBERG CUTS AA PRICE TARGET TO 20 (30) PENCE - 'SELL'

----------

BERENBERG RAISES BURFORD CAPITAL PRICE TARGET TO 820 (810) PENCE - 'BUY'

----------

RBC CUTS SPIRE HEALTHCARE TO 'SECTOR PERFORM' ('OUTPERFORM') - TARGET 100 PENCE

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2023 17:44

UK's FTSE 100 ends flat as BOJ sparks rate worries, higher on the week

AstraZeneca boosts pharma index to one-month high

*

Read more
28 Jul 2023 17:31

European shares slip overall but German blue-chips hit record high

STOXX 600 dips 0.2% but posts weekly gains

*

Read more
28 Jul 2023 12:10

AstraZeneca Q2 results beat estimates; COVID vaccine sales dry up

Q2 sales and earnings beat estimates

*

Read more
28 Jul 2023 09:13

AstraZeneca's rare disease arm in $1 bln deal for Pfizer gene therapies

July 28 (Reuters) - AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the British drugmaker bets on new genetic therapies.

Read more
28 Jul 2023 08:52

LONDON MARKET OPEN: StanChart, AstraZeneca lift FTSE 100 into green

(Alliance News) - Stock prices in London opened higher on Friday, boosted by a mostly strong set of company earnings, while investors weighed recent central bank decisions.

Read more
28 Jul 2023 08:51

TOP NEWS: AstraZeneca profit surges as Alexion agrees Pfizer deal

(Alliance News) - AstraZeneca PLC on Friday reported half-year profit more than quintupling amid much lower costs, as its rare disease focused unit Alexion signed an agreement with Pfizer.

Read more
28 Jul 2023 07:54

LONDON BRIEFING: NatWest posts interim growth; IAG swings to profit

(Alliance News) - Stocks in London are called slightly lower on Friday, with investors having plenty to consider amid the week's swathe of corporate earnings and central bank decisions.

Read more
28 Jul 2023 07:04

AstraZeneca posts strong first half despite Covid drug weakness

(Sharecast News) - Pharmaceuticals giant AstraZeneca reported strong first-half growth on Friday, despite challenges related to the decline of Covid-19 medicines.

Read more
27 Jul 2023 21:08

IN BRIEF: Astra drug approved while another shows promise

AstraZeneca PLC - Cambridge-based pharmaceutical firm - Says Soliris approved in EU for treatment of refractory generalised myasthenia gravis in those aged between six and 17. "This is the first and only targeted therapy approved for the treatment of paediatric patients with the disease in the EU," AstraZeneca says. Myasthenia gravis is a disease that causes muscle weakness. Separately, Astra says Enhertu shows meaningful progression-free survival and overall survival in some cancer sufferers. The measures are two secondary endpoints of a phase II trial. Enhertu is being jointly-developed by Astra and Daiichi Sankyo Co Ltd.

Read more
27 Jul 2023 18:07

Bristol Myers sales fall, cuts 2023 forecast as drugs face competition

Q2 revenue at $11.23 bln, misses analysts' estimate

*

Read more
25 Jul 2023 12:07

IN BRIEF: OTAQ names interim finance chief with incumbent to move on

OTAQ PLC - Lancaster, England-based marine technology company, focused on offshore oil and gas industries and aquaculture - Chief Financial Officer Matt Enright resigns effective July 31, to assume a new role outside OTAQ. He was hired as CFO in April 2020. OTAQ appoints Justine Dowds, previously managing director at GB3 Ltd until May, as interim CFO. Dowds was also finance director at Pool Aviation Ltd from 2007 to 2015, and prior to that was financial controller at United Utilities Group PLC and an accountant at AstraZeneca PLC. Enright says: "I believe the company is now well placed to benefit from the investments in resource and products made over the past three years, placing OTAQ on a sound growth path."

Read more
20 Jul 2023 14:35

Activist investor Elliott takes stake in drug manufacturer Catalent - source

LONDON, July 20 (Reuters) - Activist investor Elliott Investment has taken a stake in contract drugmaker Catalent , a source familiar with the matter told Reuters on Thursday.

Read more
18 Jul 2023 08:10

AstraZeneca, Sanofi infant respiratory treatment gets US approval

(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.

Read more
18 Jul 2023 07:48

LONDON BRIEFING: Ocado backs annual guidance as interim loss widens

(Alliance News) - Stocks in London are set to tread water on Tuesday, as investors look ahead to US corporate earnings and economic data.

Read more
18 Jul 2023 06:04

Rishi Sunak to meet bosses at inaugural Business Council gathering

(Alliance News) - Bosses from AstraZeneca PLC, Alphabet Inc's Google, Shell PLC and other major companies will gather in Downing Street on Tuesday for the first meeting of Rishi Sunak's Business Council.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.